Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US FTC approves Takeda’s $62bn acquisition of Shire
As per the cash-cum stock deal signed in early May, the Japanese pharma company offers to pay $30.33 in cash for each Shire share in addition to either
As per the cash-cum stock deal signed in early May, the Japanese pharma company offers to pay $30.33 in cash for each Shire share in addition to either
The agency said that the recall pertains to medicines which use valsartan supplied by China-based Zhejiang Huahai Pharmaceuticals. It revealed that the review was launched after Zhejiang Huahai
Lojuxta has received approval for funding as an NHS treatment for adult patients with Homozygous Familial Hypercholesterolaemia (HoFH) in England. The first in class medicine can reduce the
Apart from the approval of the UK marketing authorisation application, Alliance Pharma has also received the agency’s nod to market the prescription nausea drug under the brand name
The companies have also announced research collaboration for the development of five additional gene therapy products in neurological disorders. Benitec’s silence-and-replace gene therapy technology has been designed to deliver a
The Pennsylvania-based cannabinoid-based drug developer reported that the drug, which is delivered via a transdermal patch, could not achieve the target blood levels of 5 to 15ng/ml THC
The regulator has accepted the application for a type II variation to the marketing authorization for Rubracato include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian
The company will recruit around 450 patients in the double-blind, randomized, placebo-controlled, 48-week safety and efficacy trial. The patients will be randomized 1:1:1 to two different Anavex 2-73
As per terms of the deal, Juniper will purchase all outstanding shares of Juniper by paying $11.50 per share in cash. Juniper’s core businesses include Crinone (progesterone gel)
Aveo said that Novartis informed it that although the AV-380 Program is a key asset, the development delays of the drug and the changes in its management and